Northern Trust Corp Acquires 43,146 Shares of Immunome, Inc. (NASDAQ:IMNM)

Northern Trust Corp raised its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 9.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 516,491 shares of the company's stock after acquiring an additional 43,146 shares during the period. Northern Trust Corp owned approximately 0.65% of Immunome worth $5,485,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IMNM. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome in the fourth quarter valued at about $75,000. AlphaQuest LLC raised its holdings in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after acquiring an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after acquiring an additional 7,129 shares during the period. Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter worth approximately $95,000. Finally, Stoneridge Investment Partners LLC bought a new stake in shares of Immunome during the fourth quarter valued at approximately $123,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IMNM shares. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research note on Thursday. Wedbush reaffirmed an "outperform" rating and set a $21.00 price target (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Guggenheim reduced their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Stephens restated an "overweight" rating and set a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Lake Street Capital started coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $23.33.

Immunome Trading Up 0.4%

Immunome stock traded up $0.03 during mid-day trading on Monday, hitting $8.49. The stock had a trading volume of 527,133 shares, compared to its average volume of 915,906. The stock has a 50-day simple moving average of $7.59 and a two-hundred day simple moving average of $9.61. The stock has a market capitalization of $738.73 million, a PE ratio of -1.05 and a beta of 2.00. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Sell-side analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, CTO Philip Tsai bought 12,300 shares of the business's stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the purchase, the chief technology officer now owns 33,300 shares of the company's stock, valued at $280,386. This represents a 58.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall bought 137,100 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of $7.29 per share, with a total value of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 156,400 shares of company stock valued at $1,160,495. 8.60% of the stock is currently owned by insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.